No Data
No Data
No Data
No Data
No Data
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical
GlobeNewswireApr 24 07:47 ET
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
Yahoo FinanceApr 11 07:00 ET
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation of its DMT-based compound AP-188 for the potenti
BenzingaApr 3 16:45 ET
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment
Yahoo FinanceMar 28 08:40 ET
Algernon Pharmaceuticals Announces Closing of the Acquisition of Its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical
GlobeNewswireMar 27 12:04 ET
Algernon Pharmaceuticals Announces Closing of Private Placement
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF) (the "Company" or "Algernon") a Canadian clinical stage pharmaceutical development
GlobeNewswireDec 27, 2023 16:01 ET
No Data
No Data